Table 3. Linear regression analyses of alanine aminotransferase after HCV eradication.
| Univariate analysis | Multivariate analysis | |||
|---|---|---|---|---|
| beta (SD beta) | P | beta (SD beta) | P | |
| ALT (linear) at week 24 post treatment | ||||
| Age (years, continuous) | -0.16 (0.08) | 0.8 | ||
| Male gender | 6.67 (2.12) | 0.002 | -6.75 (2.11) | 0.002 |
| Diabetes (presence) | 1.38 (3.21) | 0.7 | ||
| Bilirubin (mg/dL, continuous) | 0.13 (1.77) | 0.9 | ||
| ALT (U/L, continuous) | 0.03 (0.01) | 0.04 | 0.03 (0.01) | 0.03 |
| γGT (U/L, continuous) | 0.01 (0.006) | 0.03 | 0.01 (0.006) | 0.02 |
| Platelets (/nl, continuous) | -0.04 (0.01) | 0.01 | -0.04 (0.014) | 0.008 |
| HCV genotype 2, 3 versus 1, 4 | -0.70 (2.29) | 0.8 | ||
| IFN-free versus IFN-based therapy | -4.24 (2.01) | 0.04 | -4.23 (1.97) | 0.03 |
| BMI (kg/m2, continuous) | 0.43 (0.16) | 0.007 | 0.43 (0.16) | 0.006 |
| ALT (linear) at week 48 post treatment | ||||
| Age (years, continuous) | -0.08 (0.09) | 0.3 | ||
| Male gender | 5.90 (2.60) | 0.02 | -7.11 (2.49) | 0.005 |
| Diabetes (presence) | 2.54 (4.30) | 0.5 | ||
| Bilirubin (mg/dL, continuous) | -2.94 (2.41) | 0.2 | ||
| ALT (U/L, continuous) | 0.02 (0.02) | 0.3 | ||
| γGT (U/L, continuous) | 0.03 (0.01) | 0.5 | 0.04 (0.01) | 0.001 |
| Platelets (/nl, continuous) | -0.04 (0.02) | 0.04 | -0.04 (0.02) | 0.03 |
| HCV genotype 2, 3 versus 1, 4 | -4.44 (2.40) | 0.06 | ||
| IFN-free versus IFN-based therapy | -3.02 (2.64) | 0.2 | ||
| BMI (kg/m2, continuous) | 0.19 (0.19) | 0.06 | ||
ALT serum concentration was analyzed as continuous variable in this model. ALT, alanine aminotransferase; BMI, body mass index; γGT, γ-glutamyl transferase; IFN, interferon; INR, international normalized ratio; IFN, interferon; ULN, upper limit of normal.